NR1D1 and hepatocellular carcinoma: Previous literature reported that SR9009 manifested marked selectivity for LXRα (also known as NR1H3) when compared with REV-ERBα [28], and LXRα suppressed FOXM1 expression in hepatocellular carcinoma [29].